Center-Authored Papers

Filters: Author is Eary, Janet F  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
Y
Yu EY, Muzi M, Hackenbracht JA, Rezvani BB, Link JM, Montgomery RB, Higano CS, Eary JF, Mankoff DA.  2011.  C11-acetate and F-18 FDG PET for men with prostate cancer bone metastases: relative findings and response to therapy.. Clinical nuclear medicine. 36(3):192-8. Abstract
S
Stanton SE, Eary JF, Marzbani EA, Mankoff D, Salazar LG, Higgins D, Childs J, Reichow J, Dang Y, Disis ML.  2016.  Concurrent SPECT/PET-CT imaging as a method for tracking adoptively transferred T-cells in vivo.. Journal for immunotherapy of cancer. 4:27. Abstract
R
Rajendran JG, Fisher DR, Gopal AK, Durack LD, Press OW, Eary JF.  2004.  High-dose (131)I-tositumomab (anti-CD20) radioimmunotherapy for non-Hodgkin's lymphoma: adjusting radiation absorbed dose to actual organ volumes.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 45(6):1059-64. Abstract
P
Pollack SM, Jungbluth AA, Hoch BL, Farrar EA, Bleakley M, Schneider DJ, Loggers ET, Rodler E, Eary JF, Conrad EU et al..  2012.  NY-ESO-1 is a ubiquitous immunotherapeutic target antigen for patients with myxoid/round cell liposarcoma.. Cancer. 118(18):4564-70. Abstract
Pollack SM, Li Y, Blaisdell MJ, Farrar EA, Chou J, Hoch BL, Loggers ET, Rodler E, Eary JF, Conrad EU et al..  2012.  NYESO-1/LAGE-1s and PRAME are targets for antigen specific T cells in chondrosarcoma following treatment with 5-Aza-2-deoxycitabine.. PloS one. 7(2):e32165. Abstract
Pollack SM, Jones RL, Farrar EA, Lai IP, Lee SM, Cao J, Pillarisetty VG, Hoch BL, Gullett A, Bleakley M et al..  2014.  Tetramer guided, cell sorter assisted production of clinical grade autologous NY-ESO-1 specific CD8(+) T cells.. Journal for immunotherapy of cancer. 2(1):36. Abstract
Peterson LM, Kurland BF, Schubert EK, Link JM, Gadi VK, Specht JM, Eary JF, Porter P, Shankar LK, Mankoff DA et al..  2013.  A Phase 2 Study of 16α-[(18)F]-fluoro-17β-estradiol Positron Emission Tomography (FES-PET) as a Marker of Hormone Sensitivity in Metastatic Breast Cancer (MBC).. Molecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging. 16(3):431-40. Abstract
Pagel JM, Appelbaum FR, Eary JF, Rajendran J, Fisher DR, Gooley T, Ruffner K, Nemecek E, Sickle E, Durack L et al..  2006.  131I-anti-CD45 antibody plus busulfan and cyclophosphamide before allogeneic hematopoietic cell transplantation for treatment of acute myeloid leukemia in first remission.. Blood. 107(5):2184-91. Abstract
G
Gopal AK, Rajendran JG, Gooley TA, Pagel JM, Fisher DR, Petersdorf SH, Maloney DG, Eary JF, Appelbaum FR, Press OW.  2007.  High-dose [131I]tositumomab (anti-CD20) radioimmunotherapy and autologous hematopoietic stem-cell transplantation for adults > or = 60 years old with relapsed or refractory B-cell lymphoma.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 25(11):1396-402. Abstract
Gopal AK, Gooley TA, Maloney DG, Petersdorf SH, Eary JF, Rajendran JG, Bush SA, Durack LD, Golden J, Martin PJ et al..  2003.  High-dose radioimmunotherapy versus conventional high-dose therapy and autologous hematopoietic stem cell transplantation for relapsed follicular non-Hodgkin lymphoma: a multivariable cohort analysis.. Blood. 102(7):2351-7. Abstract
Gopal AK, Rajendran JG, Petersdorf SH, Maloney DG, Eary JF, Wood BL, Gooley TA, Bush SA, Durack LD, Martin PJ et al..  2002.  High-dose chemo-radioimmunotherapy with autologous stem cell support for relapsed mantle cell lymphoma.. Blood. 99(9):3158-62. Abstract
E
Eary JF, Krohn KA.  2013.  Standards for reporting PET clinical trials.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 54(9):1516-7.